J Korean Med Sci.  2022 May;37(17):e130. 10.3346/jkms.2022.37.e130.

Incidence of Venous Thromboembolism: The 3 ^rd Korean Nationwide Study

• Hwang HG
• Lee JH
• Kim SA
• Kim YK
• Yhim HY
• Hong J
• Bang SM

• KMID: 2529702
• DOI: http://doi.org/10.3346/jkms.2022.37.e130

Abstract

Background
The incidence of venous thromboembolism (VTE) has gradually increased in the Korean population. This study aimed to evaluate the annual age- and sex-adjusted incidence rates (ASR) of VTE and anticoagulation trends between 2014 and 2018.
Methods
Using the Korean Health Insurance Review and Assessment Service database, we retrospectively identified VTE patients between 2014 and 2018 using both diagnostic and medication anticoagulant codes assigned within 6 months of the initial index event. Anticoagulant patterns were classified as follows: direct oral anticoagulants (DOAC), panticoagulants, warfarin, and mixed anticoagulation regimens.
Results
We identified 95,205 patients with VTE (female, 56.8%). The ASR for VTE per 100,000 person-years increased from 32.8 in 2014 to 53.7 cases in 2018 (relative risk of 1.63; 95% confidence interval, 1.6–1.67). The VTE incidence rates were 25 times higher in the ≥ 80 group than in the 30s group. VTE occurred 1.29 times more often in women than in men. The proportion of DOAC prescriptions increased from 40.5% to 72.8%, whereas warfarin prescriptions decreased from 27% to 5.6% in 2014 and 2018.
Conclusion
In Korea, the ASRs of VTE continued to increase since 2014, but the rate of increase slowed in 2018. The VTE occurred more often in the elderly and in women. Five years after the introduction of DOACs in 2013, they accounted for 73% of all anticoagulants used to treat VTE.

Keyword

Anticoagulants; Incidence; Pulmonary Embolism; Venous Thromboembolism

Figure

• 

  Fig. 1 Anticoagulation trend for venous thromboembolism from 2014 to 2018.DOAC = direct oral anticoagulants.

Reference

1. Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. 2013; 126(9):832.e13–832.e21.

2. Hong J, Lee JH, Yhim HY, Choi WI, Bang SM, Lee H, et al. Incidence of venous thromboembolism in Korea from 2009 to 2013. PLoS One. 2018; 13(1):e0191897. PMID: 29370290.

3. Sakuma M, Nakamura M, Yamada N, Ota S, Shirato K, Nakano T, et al. Venous thromboembolism: deep vein thrombosis with pulmonary embolism, deep vein thrombosis alone, and pulmonary embolism alone. Circ J. 2009; 73(2):305–309. PMID: 19096193.

4. Molina JA, Jiang ZG, Heng BH, Ong BK. Venous thromboembolism at the National Healthcare Group, Singapore. Ann Acad Med Singapore. 2009; 38(6):470–478. PMID: 19565096.

5. Lee CH, Cheng CL, Lin LJ, Tsai LM, Yang YH. Epidemiology and predictors of short-term mortality in symptomatic venous thromboembolism. Circ J. 2011; 75(8):1998–2004. PMID: 21697611.

6. Cheuk BL, Cheung GC, Cheng SW. Epidemiology of venous thromboembolism in a Chinese population. Br J Surg. 2004; 91(4):424–428. PMID: 15048741.

7. Law Y, Chan YC, Cheng SW. Epidemiological updates of venous thromboembolism in a Chinese population. Asian J Surg. 2018; 41(2):176–182. PMID: 28012866.

8. Delluc A, Tromeur C, Le Ven F, Gouillou M, Paleiron N, Bressollette L, et al. Current incidence of venous thromboembolism and comparison with 1998: a community-based study in Western France. Thromb Haemost. 2016; 116(5):967–974. PMID: 27465905.

9. Bouée S, Emery C, Samson A, Gourmelen J, Bailly C, Cotté FE. Incidence of venous thromboembolism in France: a retrospective analysis of a national insurance claims database. Thromb J. 2016; 14(1):4. PMID: 26900350.

10. Alotaibi GS, Wu C, Senthilselvan A, McMurtry MS. Secular trends in incidence and mortality of acute venous thromboembolism: the AB-VTE population-based study. Am J Med. 2016; 129(8):879.e19–879.e25.

11. Johansson M, Johansson L, Lind M. Incidence of venous thromboembolism in northern Sweden (VEINS): a population-based study. Thromb J. 2014; 12(1):6. PMID: 24593768.

12. Spencer FA, Emery C, Joffe SW, Pacifico L, Lessard D, Reed G, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis. 2009; 28(4):401–409. PMID: 19629642.

13. Heit JA, Ashrani A, Crusan DJ, McBane RD, Petterson TM, Bailey KR. Reasons for the persistent incidence of venous thromboembolism. Thromb Haemost. 2017; 117(2):390–400. PMID: 27975103.

14. Lehnert P, Lange T, Møller CH, Olsen PS, Carlsen J. Acute pulmonary embolism in a National Danish Cohort: increasing incidence and decreasing mortality. Thromb Haemost. 2018; 118(3):539–546. PMID: 29536465.

15. Jang MJ, Bang SM, Oh D. Incidence of venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemost. 2011; 9(1):85–91. PMID: 20942850.

16. Hwang HG, Lee JH, Hong J, Kim SA, Kim YK, Kim MS, et al. Recurrence of cancer-associated venous thromboembolism between 2009 and 2013: a nationwide Korean study. Clinical & Experimental Thrombosis and Hemostasis. 2021; 7(1):14–19.

17. Kim L, Kim JA, Kim S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health. 2014; 36:e2014008. PMID: 25078381.

18. Utilization of Medical Services by Region in 2014. The 2014 Statistical Yearbook on Utilization of Medical Services by Region 2015. Volume 1.

19. Jang MJ, Bang SM, Oh D. Incidence of pregnancy-associated venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemost. 2011; 9(12):2519–2521. PMID: 21951997.

20. Clegg LX, Hankey BF, Tiwari R, Feuer EJ, Edwards BK. Estimating average annual per cent change in trend analysis. Stat Med. 2009; 28(29):3670–3682. PMID: 19856324.

21. Raskob GE, Angchaisuksiri P, Blanco AN, Büller H, Gallus A, Hunt BJ, et al. Thrombosis: a major contributor to global disease burden. Semin Thromb Hemost. 2014; 40(7):724–735. PMID: 25302681.

22. Park ES, Choi HS, Lee KS, Kim SW, Lee JM. Venous thromboembolism in children and young adults in Korea: analysis of the Korean Health Insurance Review and Assessment Service Database. J Korean Med Sci. 2019; 34(49):e316. PMID: 31858756.

23. Park TY, Jung JW, Choi JC, Shin JW, Kim JY, Choi BW, et al. Epidemiological trend of pulmonary thromboembolism at a tertiary hospital in Korea. Korean J Intern Med. 2017; 32(6):1037–1044. PMID: 28286939.

24. Kim SA, Yhim HY, Bang SM. Current management of cancer-associated venous thromboembolism: focus on direct oral anticoagulants. J Korean Med Sci. 2019; 34(6):e52. PMID: 30787683.

25. Stevens JA, Olson S. Reducing falls and resulting hip fractures among older women. MMWR Recomm Rep. 2000; 49(RR-2):3–12.

26. White RH. The epidemiology of venous thromboembolism. Circulation. 2003; 107(23):Suppl 1. I4–I8. PMID: 12814979.

27. Boardman HM, Hartley L, Eisinga A, Main C, Roqué i Figuls M, Bonfill Cosp X, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015; (3):CD002229. PMID: 25754617.

28. Weitz JI, Haas S, Ageno W, Goldhaber SZ, Turpie AG, Goto S, et al. Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. J Thromb Thrombolysis. 2020; 50(2):267–277. PMID: 32583306.

29. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020; 382(17):1599–1607. PMID: 32223112.

30. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018; 36(20):2017–2023. PMID: 29746227.

31. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018; 378(7):615–624. PMID: 29231094.